Descripción de negocio
CSL is a global specialty biotherapeutics company that develops and delivers innovative biotherapies that save lives, and help people with life-threatening medical conditions live full lives. CSL has acquired a number of companies. They include: Aventis Behring, which is now known as global biotech leader CSL Behring, U.S. plasma collector Nabi, which helped to form the world's premier plasma collection company in CSL Plasma, the Novartis influenza vaccine business, now integrated and known as Seqirus, the world's second largest influenza vaccines company and Calimmune, a leader in gene-modification and cell delivery technology.
Consejo de gestión & Consejo de supervisión
| CEO |
| Paul Perreault |
| Consejo de gestión |
| Alan Wills, Bill Campbell, Bill Mezzanotte, Elizabeth Walker, Greg Boss, John Levy, Mark Hill, Paul McKenzie |
| Consejo de supervisión |
| Dr. Brian McNamee, Abbas Hussain, Bruce Brook, Carolyn Hewson, Dr. Megan Clark, Fiona Mead, Marie McDonald, Pascal Soriot, Paul Perreault, Professor Andrew Cuthbertson |
Datos de la empresa
| Nombre: |
CSL Ltd. |
| Dirección: |
Poplar Road 45,Parkville VIC 3052, Australia |
| Teléfono: |
+61-3-9389-1911 |
| Fax: |
+61-3-9389-1434 |
| E-mail: |
-
|
| Internet: |
www.csl.com.au/ |
| Industria: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Subsector: |
Pharmaceuticals |
| Fin del año financiero: |
30/06 |
| Acciones de libre circulación: |
42.01% |
| Fecha de OPI: |
30/05/1994 |
Relación con inversores
| Nombre: |
Mark Dehring |
| IR teléfono: |
+61-3-9389-3407 |
| IR-fax: |
- |
| IR e-mail: |
mark.dehring@csl.com.au
|
